When paired with willing older adults, talking AI can administer and assess preliminary dementia tests in much the same way—and with similar effectiveness—as human specialists.

Why do investors equate these companies with beautiful, mythical beasts? Because startups with such dazzling attributes are—or long were—rarely seen.

Where a cautious President Biden wanted to confine American AI know-how to America, a freewheeling President Trump wants to turn it loose—at least to select friends and allies.

For some, the FDA is moving too fast in its drive to adopt generative AI agency-wide. 

Healthcare consumers considering the use of large language AI for mental healthcare are apt to shy away from the technology if they feel it might put their privacy at risk. 

The FDA is getting AI-aggressive about speeding up device reviews. Its plan is to unleash generative AI on tedious and repetitive tasks.

What attributes tend to nudge clinicians toward accepting AI into their work lives? Several, of course—but the most broadly determinative can be trimmed to just two. 

Give healthcare workers AI to do their jobs and you might make them AI-dependent. Give them AI anyway?